CANNAINVESTOR Magazine U.S. Publicly Traded April 2018 | Page 73

Our Products Launched in late spring 2017, Evolve Formulas’ game-changing transdermal product NanoSerum™, enables cannabis to be rapidly absorbed into systemic circulation for direct-focus relief from pain, inflammation and anxiety. NanoSphere will offer two more product applications under the brand name Evolve: an intra-nasal delivery and an intra-oral delivery. Each application will be offered in varying strengths and strains. CSE: NSHS Strong Top-Line Growth Sustainable top-line revenue growth leading technology Diversified growing platforms Targeted geographic expansion Shares Issued 96.1M 9.8M Fully Diluted Market Cap 105.9M Investment Highlights Warrants/Options $79M Management Robert Sutton , Chairman and CEO Operational Excellence Robust pipeline of new and innovative products Rapid, scalable, cost-efficient and proprietary manufacturing process First & ONLY pharma- ceutical delivery system for commercial products Solid and expanding IP portfolio Share Structure As of Dec. 5, 2017 Disruptive Technology Unparalleled IP that can be leveraged and licensed throughout the world across multiple industry channels Ongoing & comprehensive clinical trials and testing protocols Category Leadership First and only commercial nanotechnology platform Innovation driven to address unmet needs Award-winning product in cannabis industry David Sutton , President and COO Richard Clark Kaufman PhD, Chief Science Officer Terry Grossman , Chief Medical Officer Victor Gonclaves , Executive Vice President Bennett Liu , CFO Contact US Corporate Contact 600 - 8400 E. Crescent Parkway Greenwood Village, CO 80111 www.nanospherehealth.com 720.528.4437 [email protected] Canada Contact 488 - 1090 West Georgia Street Vancouver, British Columbia Victor Goncalves 204-997-5517 [email protected]